Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

about

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

Item

http://www.wikidata.org/entity/Q58038937

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Dolutegravir for first-line an ...... or implementation and research

@en

Dolutegravir for first-line an ...... or implementation and research

@nl

type

Item

label

Dolutegravir for first-line an ...... or implementation and research

@en

Dolutegravir for first-line an ...... or implementation and research

@nl

prefLabel

Dolutegravir for first-line an ...... or implementation and research

@en

Dolutegravir for first-line an ...... or implementation and research

@nl

P1476

Dolutegravir for first-line an ...... or implementation and research

@en

P2093

Paul K Drain

http://www.w3.org/2001/XMLSchema#string

Tulio de Oliveira

http://www.w3.org/2001/XMLSchema#string

Yogan Pillay

http://www.w3.org/2001/XMLSchema#string

P2860

High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.

Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Viral load monitoring as a tool to reinforce adherence: a systematic review.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

P304

e400-e404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S2352-3018(18)30093-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29884404

http://www.w3.org/2001/XMLSchema#string

P932

6063784

http://www.w3.org/2001/XMLSchema#string